**Rejection Under 35 U.S.C. §102(b)**

Claims 1 and 3 are rejected under 35 U.S.C. 102(b) as being anticipated by Boesenberg et al. Boesenberg et al teaches reacting to amino acids with 2-chlorobenzoxazole. Claims 1 and 3 have been cancelled.

Claims 1 and 3 are rejected under 35 U.S.C. 102(b) as being anticipated by Lazer et al. Lazer et al. teaches reacting 2-benzoxazole with amino acids. Claims 1 and 3 have been cancelled.

Claims 1 and 3 are rejected under 35 U.S.C. 102(b) as being anticipated by Advani et al article. The Advani et al article teaches reacting amino acids with 2-chlorobenzoxazole. Claims 1 and 3 have been cancelled.


**REMARKS**

Claim 2 has been allowed. Claims 1 and 3 have been cancelled.

The amendment filed August 31, 2001 is objected to under 35 U.S.C. 132 because it introduces new matter into the disclosure. Applicants request cancellation of the Sequence Listing set forth on page 3 of the amendment filed August 8, 2003 in response to the requirement for a sequence listing mailed by the United States Patent and Trademark Office on July 5, 2001. The proposed amendments to the specification now contain an instruction before each replacement paragraph.

Based on the foregoing, it is believed that the presently pending claims are in form for allowance. Reconsideration and early allowance are respectfully requested.

Respectfully submitted,



Soma G. Simon
Attorney for Applicants
Registration No. 37,444

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5019
Facsimile (610) 270-5090
N:\SOMA\CASES\p50868\ResptoRej2.doc